| |
|
| |
|
| |
Welcome to PharmaShots Weekly
| Apr 27, 2026 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
UCB’s $1.15B Bet on Cell Therapy
|
|
| | Amneal Buys Kashiv to Boost Biosimilars
|
|
| | Medtronic Backs Pulnovo with $100M
|
|
| | PharmaShots Awards Set for May 1: Celebrating Industry Excellence
|
|
|
|
|
Stay Curious.
| Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
|
|
Cover Story
|
| • | Lilly’s $7B Kelonia Buyout Supercharges In Vivo CAR-T and Genetic Medicines
|
|
Strategic Deals & Partnerships
|
| • | Biogen Consolidates Global Felzartamab Rights with TJ Bio Greater China Deal
|
|
| • | Merck & Google Cloud Launch $1B Agentic AI Partnership
|
|
Funding & Investments
|
| • | Pulnovo–Medtronic Alliance Raises $100M to Accelerate PADN Commercialization
|
|
Mergers & Acquisitions (M&A)
|
| • | UCB Acquires Neurona Therapeutics in $1.15B Regenerative Neuroscience Bet
|
|
| • | Amneal Acquires Kashiv BioSciences to Build Global Biosimilars Platform
|
|
| • | Cumberland Divests Branded Portfolio to Apotex in $100M Strategic Pivot
|
|
Clinical Trials & Data Readouts
|
Oncology
|
| • | EpiBiologics Initiates Phase I Study of EPI-326 (EGFR Degrader)
|
|
| • | Innate Pharma Reports Phase II MATISSE Data for IPH5201 in NSCLC
|
|
| • | Pheast Therapeutics Shares Early Data for PHST001 (CD24 mAb)
|
|
| • | Akeso Reports Phase II COMPASSION-26 Data in Pancreatic Cancer
|
|
| • | Mabwell Advances 9MW2821 into Phase III for TNBC
|
|
Respiratory & Immunology
|
| • | AstraZeneca’s Phase III MIRANDA Trial for Tozorakimab in COPD
|
|
Rare Diseases & Hematology
|
| • | Novo Nordisk Reports Phase III HIBISCUS Data for Etavopivat in SCD
|
|
| • | Monopar Therapeutics Shares Phase III Data for ALXN1840 in Wilson Disease
|
|
Neurology
|
| • | Genentech Reports Phase III METEOROID Data for Enspryng in MOGAD
|
|
Autoimmune & Immunology
|
| • | Regeneron Reports Phase III NIMBLE Data for Cemdisiran in gMG
|
|
| • | J&J Shares Phase III Vivacity-MG3 Data for Nipocalimab in gMG
|
|
Nephrology
|
| • | AstraZeneca Reports Phase III I CAN Data for Ultomiris in IgAN
|
|
Metabolic Disorders
|
| • | Novo Nordisk Reports Phase IIIa PIONEER TEENS Data for Oral Semaglutide
|
|
Regulatory Watch
|
| • | FDA Priority Review: Padcev + Keytruda in MIBC (Astellas & Pfizer)
|
|
| • | FDA Approval: Tzield (Sanofi) for Type 1 Diabetes Delay
|
|
| • | FDA Approval: Idvynso (Merck) for HIV-1
|
|
| • | EU Conditional Approval: Ojemda (Ipsen)
|
|
| • | FDA Approval: Dupixent (Regeneron & Sanofi) for CSU
|
|
| • | FDA IND Clearance: DMX-1001 (DemeRx) for Alcohol Use Disorder
|
|
| • | FDA Accelerated Approval: Otarmeni (Regeneron) for Genetic Hearing Loss
|
|
| • | CHMP Positive Opinion: Redemplo (Arrowhead) for FCS
|
|
| • | Health Canada Approval: Bosaya & Vevzuo (Biocon)
|
|
MedTech & Diagnostics
|
| • | FLEX Vascular Reports Positive 12-Month AV Registry Data
|
|
| • | Utepreva Launches Next-Gen Endometrial Sampler for Early Cancer Detection
|
|
|
|
| |
Innovation. Leadership. Breakthroughs.
|
The global pharmaceutical and healthcare landscape is evolving at an unprecedented pace, driven by visionary leadership, cutting-edge science, and technologies that are redefining patient care.
|
PharmaShots Awards 2026 is your front-row seat to this transformation—a premier virtual event honoring the organizations and leaders who are pushing the boundaries of innovation across the life sciences ecosystem.
|
From drug discovery and biopharma breakthroughs to medtech, diagnostics, and digital health, these awards celebrate the pioneers shaping the future of healthcare and driving real-world impact.
|
Awards Announcement: May 1, 2026
Virtual Global Event: Register Here
|
Join industry leaders, innovators, and decision-makers worldwide to recognize excellence, vision, and the breakthroughs that are changing lives. Every achievement that transforms healthcare deserves to be celebrated.
|
Interested in exploring sponsorship opportunities?
Partner with us at the PharmaShots Pharma Awards, fill out your sponsorship form here
|
|
|
Lilly’s $7B Kelonia Buyout Supercharges In Vivo CAR-T and Genetic Medicines
|
|
Eli Lilly has entered into a definitive agreement to acquire Kelonia Therapeutics, expanding Lilly’s genetic medicine capabilities and adding a next-generation in vivo CAR-T platform to its oncology portfolio.
|
Why It Matters
|
| • | Deal Value: Up to ~$7B in cash, including $3.25B upfront and up to $3.75B in milestone-based contingent payments.
|
|
| • | Platform Expansion: Adds Kelonia’s iGPS in vivo gene delivery and integration technology, with potential applications well beyond multiple myeloma.
|
|
| • | Clinical Validation: KLN-1010 has shown promising early safety and efficacy, providing initial human proof-of-concept for in vivo CAR-T.
|
|
Strategic Focus
|
| • | In Vivo CAR-T Leadership: Positions Lilly at the forefront of in vivo CAR-T approaches that could sidestep complex, individualized ex vivo manufacturing and pre-conditioning chemo.
|
|
| • | Oncology Depth: Strengthens Lilly’s oncology pipeline with a potentially transformative multiple myeloma therapy targeting BCMA.
|
|
| • | Broader Genetic Medicine Play: Lilly views iGPS as a modular platform that can be extended to additional targets and diseases, aligning with its long-term genetic medicine strategy.
|
|
|
| | Strategic Deals & Partnerships
|
|
|
|
|
Biogen Locks Global Felzartamab Rights in China Deal
|
|
TJ Bio has granted Biogen exclusive rights to felzartamab in the Greater China Region, giving Biogen full worldwide ownership of the late-stage CD38-targeting antibody as it advances through Phase III trials across multiple immune-mediated diseases.
|
Why It Matters
|
| • | Deal Value: $100M upfront plus up to ~$750M in potential commercial and sales milestones, and tiered mid-single- to low-double-digit royalties on Greater China net sales.
|
|
| • | Global Control: Biogen now holds exclusive worldwide rights to felzartamab, simplifying governance and enabling a unified global development and commercialization strategy.
|
|
| • | Risk Transfer: Biogen takes over TJ Bio’s MorphoSys-related milestone and royalty obligations, further de-risking TJ Bio’s balance sheet.
|
|
Strategic Focus
|
| • | Regional Execution: Biogen will drive clinical development, regulatory interactions, commercialization, and post-approval lifecycle management for felzartamab across Greater China.
|
|
| • | Manufacturing Model: For the multiple myeloma indication, TJ Bio will remain the manufacturer at its Hangzhou GMP facility, ensuring local supply while Biogen leads market strategy.
|
|
| • | Pipeline Synergy: Consolidated rights enable Biogen to fully align its global Phase III programs in antibody-mediated rejection, IgA nephropathy, and primary membranous nephropathy with regional plans in China.
|
|
|
Merck & Google Cloud Launch $1B Agentic AI Partnership to Power the Next Era of Biopharma
|
|
Merck has entered a multi-year strategic partnership with Google Cloud, committing up to $1 billion to deploy an AI-driven, agentic platform across its research and development, manufacturing, commercial, and corporate functions.
|
Why It Matters
|
| • | Scale of Investment: Up to $1B over multiple years devoted to AI infrastructure, engineering support, and Gemini Enterprise licensing.
|
|
| • | Enterprise-Wide Scope: Agentic AI platform will span R&D, manufacturing, commercial, and corporate functions, touching ~75,000 employees.
|
|
| • | Productivity & Digitization: Focus on digitizing data, automating routine tasks, and augmenting decision-making to unlock new levels of efficiency and innovation.
|
|
Strategic Focus
|
| • | R&D Acceleration: Use AI agents to streamline target identification, molecule design, and clinical trial planning, shortening development timelines.
|
|
| • | Smart Manufacturing: Apply predictive analytics and intelligent automation to reduce downtime, improve quality, and strengthen supply chain resilience.
|
|
| • | Data-Driven Engagement: Enable more tailored, insight-driven interactions with patients and healthcare providers, enhancing outcomes and commercial impact.
|
|
|
| | Pulnovo–Medtronic Raise $100M to Scale PADN Globally
|
|
|
|
|
Medtronic Backs Pulnovo’s PADN with $100M Funding
|
|
Pulnovo Medical has completed an oversubscribed $100M strategic financing round led by Medtronic, with continued participation from existing investors EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures, alongside new investor HSG (formerly Sequoia China).
|
Why It Matters
|
| • | Financing Scale: $100M oversubscribed round anchored by Medtronic, with strong support from top-tier global investors.
|
|
| • | Strategic Commercial Pact: Commercial agreement contemplates future global PADN commercialization using Medtronic’s far-reaching channels.
|
|
| • | Clinical & Regulatory Momentum: Funds back IDE trials in the US and global regulatory submissions, reinforcing PADN’s path toward broader adoption.
|
|
Strategic Focus
|
| • | Pulmonary Hypertension & HF: PADN is aimed at patients with pulmonary hypertension and heart failure, including groups with limited or no approved treatment options.
|
|
| • | Global Scale-Up: Partnership positions Pulnovo to pair its innovation with Medtronic’s scale for faster global market penetration.
|
|
| • | Evidence Generation: Ongoing and newly initiated trials in Europe, Asia, and the US (including PULSE-LHD IDE) are designed to strengthen the evidence base for PADN’s safety and efficacy.
|
|
|
| | Mergers & Acquisitions (M&A)
|
|
|
|
|
UCB Bets $1.15B on Regenerative Cell Therapy with Neurona Therapeutics Acquisition
|
|
UCB has entered into a definitive agreement to acquire Neurona Therapeutics, deepening UCB’s leadership in epilepsy and expanding its reach into next-generation, disease-modifying regenerative therapies for neurological disorders.
|
Why It Matters
|
| • | Deal Value: Up to $1.15B total, including $650M upfront and up to $500M in milestones.
|
|
| • | Strategic Fit: Builds on UCB’s 30-year epilepsy franchise (e.g., levetiracetam, brivaracetam) and moves it into cell therapy-based neural repair.
|
|
| • | Regulatory Tailwinds: RMAT and PRIME designations provide enhanced regulatory support, including intensive guidance and potential for expedited pathways.
|
|
Strategic Focus
|
| • | Regenerative Neuroscience: Positions UCB at the forefront of regenerative approaches for drug-resistant epilepsy, a population with major unmet need.
|
|
| • | Single-Dose Durability: NRTX-1001’s one-time, potentially long-lasting mechanism could transform chronic daily treatment paradigms.
|
|
| • | Pipeline Platform: The underlying neuronal cell therapy platform may be extendable to other focal epilepsies and CNS disorders over time.
|
|
|
Amneal Builds a Global Biosimilars Engine with Kashiv BioSciences Buyout
|
Amneal Pharmaceuticals has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, significantly accelerating its biosimilar pipeline and strengthening its U.S. commercial position in affordable biologics.
|
Why It Matters
|
| • | Deal Value: Up to roughly $1.1B total consideration ($375M cash + $375M equity + up to ~$350M in milestones and royalties).
|
|
| • | Platform Creation: Establishes Amneal as a fully integrated global biosimilars leader at scale, positioned ahead of a >$300B biologics loss-of-exclusivity wave.
|
|
| • | Pipeline Acceleration: Immediately expands Amneal’s biosimilar development portfolio and manufacturing footprint in the U.S. and India.
|
|
Strategic Focus
|
| • | End-to-End Biosimilars: Integrates Kashiv’s R&D and manufacturing with Amneal’s robust U.S. commercial infrastructure for a seamless lab-to-market pathway.
|
|
| • | Affordable Biologics: Supports Amneal’s mission to expand access to high-quality, lower-cost biologic medicines for patients and health systems.
|
|
| • | Long-Term Growth: Expected to drive a steady cadence of biosimilar launches, underpinning durable revenue and EBITDA expansion beyond 2026.
|
|
|
Cumberland’s $100M Apotex Deal Refocuses Company on Orphan Drug Pipeline
|
|
Cumberland Pharmaceuticals has entered into an agreement to sell its portfolio of branded U.S. products to an affiliate of Apotex.
|
Why It Matters
|
| • | Deal Value: $100M in cash for Cumberland’s U.S. branded pharmaceuticals portfolio, providing non-dilutive capital to fund pipeline development.
|
|
| • | Strategic Pivot: Enables Cumberland to transition from a mixed commercial/R&D model toward a more focused, development-stage profile centered on orphan and specialty medicines.
|
|
| • | R&D Continuity: Cumberland retains all pipeline product candidates and its majority stake in Cumberland Emerging Technologies, preserving long-term innovation optionality.
|
|
Strategic Focus
|
| • | Orphan-Driven Growth: Concentrates resources on advancing ifetroban and other late-stage candidates across fibrotic and autoimmune indications.
|
|
| • | Lean, R&D-Centric Model: Reduces commercial complexity while leveraging partners like Apotex to maximize the value of existing brands.
|
|
| • | Specialty Medicines Platform: The Apotex alliance creates a larger platform for specialty medicines in the U.S., potentially supporting future collaborations on Cumberland-originated products.
|
|
|
| | Clinical Trials & Data Readouts
|
|
|
|
|
Phase I trial of EPI-326
|
|
EGFR-Driven Solid Tumors
|
EpiBiologics doses the first patient in a global Phase I trial of EPI-326, a tissue-selective bispecific EGFR degrader, in advanced solid tumors.
|
Key Details
|
| • | First-in-human study evaluates safety, tolerability, PK, and preliminary anti-tumor activity of EPI-326 monotherapy in NSCLC and HNSCC, with planned expansion into colorectal cancer.
|
|
Asset Snapshot
|
Tissue-selective, mutation-agnostic EGFR bispecific with robust preclinical anti-tumor activity in EGFR-mutant and wild-type models, favorable tolerability without stereotypical EGFR toxicities, and strong combination potential with TKIs and KRAS inhibitors.
|
|
Resectable NSCLC (Perioperative IO)
|
|
Innate Pharma will present interim Phase II MATISSE data (n=40) for IPH5201 at AACR 2026, highlighting early efficacy in resectable NSCLC.
|
Key Details
|
| • | IPH5201 (anti-CD39) plus durvalumab and platinum-based chemotherapy achieved pCR rates of 35.7% in tumors with PD-L1 ≥1% and 50% in PD-L1 ≥50%.
|
|
Next Steps
|
MATISSE continues enrollment in PD-L1–positive patients (PD-L1 ≥1%), supporting further investigation of dual CD39 and PD-L1 inhibition as a perioperative strategy.
|
Asset Snapshot
|
First-in-class anti-CD39 mAb designed to disrupt the adenosine axis and enhance PD-L1 blockade–based immunotherapy in early-stage lung cancer.
|
|
COPD (Exacerbation Risk)
|
AstraZeneca reports that Phase III MIRANDA met its primary endpoint, with tozorakimab 300 mg Q2W significantly reducing the annualized rate of moderate-to-severe COPD exacerbations in patients who remained exacerbation-prone on inhaled standard of care.
|
Key Details
|
| • | MIRANDA enrolled 1,454 patients receiving tozorakimab 300 mg or placebo on top of optimized inhaled therapy every two weeks, including former and current smokers across all eosinophil levels and lung-function severities.
|
|
Next Steps
|
MIRANDA is the third positive Phase III COPD trial for tozorakimab (after OBERON and TITANIA), supporting planned regulatory submissions.
|
Asset Snapshot
|
First-in-class anti–IL-33 biologic showing consistent exacerbation reduction on top of inhaled SoC across broad COPD populations.
|
|
Advanced Solid Tumors
|
|
Pheast Therapeutics presents initial Phase Ia data for PHST001 at AACR 2026, showing target engagement, innate immune activation, and early clinical activity.
|
Key Details
|
| • | PHST001 (IgG4 anti-CD24 macrophage checkpoint inhibitor) was generally well tolerated across dose-escalation cohorts, with mostly Grade 1–2 TRAEs, and showed early signs of activity including tumor shrinkage and durable disease stabilization.
|
|
Next Steps
|
Ongoing Phase Ib combination cohorts are evaluating PHST001 with chemotherapy based on strong preclinical synergy.
|
Asset Snapshot
|
Macrophage-checkpoint–targeting anti-CD24 mAb that, in preclinical models, enhanced tumor control and survival when combined with chemotherapy and ADCs, supporting broad combination potential.
|
|
Sickle Cell Disease (SCD)
|
Novo Nordisk reports that Phase III HIBISCUS met both co-primary endpoints for etavopivat, reducing vaso-occlusive crises (VOCs) and improving haemoglobin response in SCD.
|
Key Details
|
| • | In 385 patients (≥12 years), etavopivat 400 mg once daily vs. placebo reduced the annualised VOC rate by 27% and prolonged median time to first VOC to 38.4 vs. 20.9 weeks.
|
|
| • | Haemoglobin response (>1 g/dL increase at Week 24) was achieved in 48.7% on etavopivat vs. 7.2% on placebo, with additional exploratory reductions in transfusion risk.
|
|
Next Steps
|
Novo Nordisk plans regulatory submissions for etavopivat in H2 2026.
|
Asset Snapshot
|
First-in-class oral PKR activator offering dual benefits on VOC reduction and haemoglobin improvement in SCD.
|
|
Wilson Disease (Neurologic)
|
Monopar Therapeutics presents Phase III FoCus data for ALXN1840 (tiomolibdate choline; TMC) vs. standard of care in Wilson disease patients with baseline neurologic symptoms at AAN 2026.
|
Key Details
|
| • | In neurologic patients (ALXN1840 n=77; SoC n=35), Week 48 neurologic worsening occurred in 9% vs. 25%, while neurologic improvement was 45% vs. 32%; CGI-S improvement from baseline was 61% vs. 17%, and CGI-I improvement was 47% vs. 19% with ALXN1840 vs. SoC.
|
|
| • | Durable neurologic benefit on ALXN1840 was sustained for ~3 years, with consistent efficacy in both treatment-naïve and treatment-experienced patients.
|
|
Next Steps
|
Monopar plans to submit an NDA for ALXN1840 to the US FDA in mid-2026.
|
Asset Snapshot
|
First-in-class albumin tripartite complex activator that tightly sequesters excess copper, aiming to improve neurologic outcomes vs. current chelation-based SoC.
|
|
Advanced Pancreatic Ductal Adenocarcinoma (1L)
|
|
Akeso reports Phase II COMPASSION-26 data for cadonilimab + chemotherapy as first-line therapy in advanced PDAC, presented at AACR 2026.
|
Key Details
|
| • | As of Oct 20, 2025 (median follow-up >2 years), patients with locally advanced disease achieved median PFS 11.1 months and median OS >23 months, with 12- and 24-month OS rates of 91.7% and 44.1%, respectively.
|
|
| • | Among evaluable patients (95% with ≥1 post-baseline scan), ORR was 33.9% and DCR 96.4%, with consistent responses across locally advanced and metastatic subgroups.
|
|
Asset Snapshot
|
First-in-class PD-1/CTLA-4 bispecific antibody delivering robust, durable survival and tumor control signals in 1L PDAC in combination with chemotherapy.
|
|
MOGAD (Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease)
|
Genentech reports Phase III METEOROID data for Enspryng (satralizumab; 60/120/180 mg SC by body weight at Weeks 0, 2, 4, then Q4W) vs. placebo in patients ≥12 years with MOGAD.
|
Key Details
|
| • | Primary endpoint met: 87% of Enspryng-treated patients were relapse-free at Week 48 vs. 67% on placebo, with onset of response from Week 8 and consistent effects across prespecified subgroups.
|
|
| • | Key secondaries: 66% reduction in annualized relapse rate, 79% reduction in MRI-detected active CNS lesions (optic nerves, brain, spinal cord), 73% lower need for rescue therapy, and a 17% numerical reduction in annualized inpatient hospitalizations.
|
|
Next Steps
|
Results, presented at AAN 2026, will be submitted to regulators worldwide to seek approval of Enspryng as a first treatment for MOGAD.
|
Asset Snapshot
|
Subcutaneous IL-6 receptor inhibitor with established NMOSD indications, now showing robust relapse prevention and CNS anti-inflammatory effects in MOGAD.
|
|
Generalized Myasthenia Gravis (gMG)
|
Regeneron reports Phase III NIMBLE data in adults with symptomatic gMG and anti-AChR antibodies, randomizing patients to cemdisiran monotherapy (600 mg SC Q12W), pozelimab monotherapy (200 mg Q4W), cemdisiran + pozelimab (200 mg each Q4W), or placebo (Q4W).
|
Key Details (Cemdisiran vs. Placebo)
|
| • | Cemdisiran (n=64) vs. placebo (n=59) improved gMG symptoms within 2 weeks and sustained benefit to Week 24: MG-ADL least-squares mean change −4.5 vs. −2.2 (primary endpoint), with 76.6% vs. 44.1% achieving ≥3‑point MG-ADL improvement.
|
|
| • | QMG improved by −4.2 vs. −1.5 points, with 48.4% vs. 19% achieving ≥5‑point improvement; results were presented at AAN 2026 and published in The Lancet.
|
|
Next Steps
|
Cemdisiran is under FDA review following a Q1 2026 submission, with additional global filings, including in the EU, planned during 2026.
|
Asset Snapshot
|
Quarterly SC siRNA targeting complement C5, offering rapid, deep, and sustained disease control as a convenient first-in-class RNAi option for gMG.
|
|
IgA Nephropathy (IgAN)
|
|
AstraZeneca reports positive global Phase III I CAN (ALXN1210-IgAN-320) data for IV Ultomiris vs. placebo in ~510 adults with IgAN at risk of disease progression.
|
Key Details
|
| • | Trial met its first primary endpoint: statistically significant, clinically meaningful reduction in proteinuria based on 24‑hour UPCR at Week 34, with effects evident as early as Week 10; the second primary endpoint, change in eGFR, will be assessed at Week 106.
|
|
Next Steps
|
AstraZeneca plans to seek accelerated approvals in key markets and will present full I CAN results at an upcoming medical conference.
|
Asset Snapshot
|
Long-acting C5 complement inhibitor delivering immediate, complete, and sustained terminal complement blockade, aiming to prevent complement-driven immune damage in IgAN.
|
|
Pediatric Type 2 Diabetes (10–17 Years)
|
Novo Nordisk reports Phase IIIa PIONEER TEENS results for once-daily oral semaglutide (3, 7, or 14 mg) vs. placebo added to metformin, basal insulin, or both in 132 children and adolescents with type 2 diabetes.
|
Key Details
|
| • | At Week 26, oral semaglutide achieved a superior HbA1c reduction vs. placebo, lowering blood sugar by 0.83%, with a safety profile consistent with prior semaglutide trials.
|
|
Next Steps
|
Oral semaglutide, marketed as Rybelsus in the US/EU and launching as Ozempic pill in the US, will be the subject of pediatric label-expansion filings for both brands in the US and EU in H2 2026.
|
Asset Snapshot
|
First oral GLP-1 RA evaluated in youths with type 2 diabetes, offering a non-injectable option to improve glycemic control on top of standard background therapy.
|
|
Generalized Myasthenia Gravis (gMG)
|
J&J shares Phase III Vivacity-MG3 and ongoing OLE data for Imaavy (nipocalimab) in adults with gMG, while enrollment continues in the head-to-head EPIC trial versus efgartigimod.
|
Key Details (Vivacity-MG3 & Post-hoc Analysis)
|
| • | Vivacity-MG3 randomized adults with symptomatic gMG and anti-AChR antibodies to Imaavy + SoC vs. placebo + SoC; over 24 weeks, Imaavy-treated patients were about four times more likely to achieve sustained minimal symptom expression (MSE; MG-ADL 0/1 for ≥8 weeks), with those reaching sustained MSE showing the greatest quality-of-life gains.
|
|
Key Details (OLE, up to 96 Weeks)
|
| • | In the open-label extension through 96 weeks, Imaavy produced sustained improvements in MG-ADL (−6.47) and QMG (−5.97), with 50% of patients achieving MSE and ~32% achieving sustained MSE for ≥8 weeks; total IgG was reduced by >64%, and 57% of patients were able to taper corticosteroids to ≤10 or ≤5 mg/day.
|
|
Next Steps
|
The ongoing Phase III EPIC trial is directly comparing Imaavy with efgartigimod in FcRn-naïve adults and in those switching from efgartigimod, to further define Imaavy’s role in gMG treatment.
|
Asset Snapshot
|
High-affinity FcRn blocker that rapidly and sustainably lowers pathogenic IgG, delivering deep symptom control and steroid-sparing potential in antibody-positive gMG.
|
|
Triple-Negative Breast Cancer (TNBC)
|
|
Mabwell initiates a Phase III trial of 9MW2821 in locally advanced or metastatic TNBC, marking the fourth pivotal study for this Nectin‑4–targeting ADC.
|
Key Details
|
| • | Randomized, open-label trial compares 9MW2821 vs. investigator’s choice chemotherapy in TNBC patients previously treated with taxane-based chemotherapy ± immunotherapy and a topoisomerase inhibitor–based ADC.
|
|
Next Steps
|
9MW2821 is already in Phase III development for urothelial carcinoma and cervical cancer, with a U.S. study in ADC‑treated TNBC underway and first patient dosed in August 2025.
|
Asset Snapshot
|
Next-generation, Nectin‑4–targeting ADC (bulumtatug fuvedotin) with encouraging multi-tumor activity and FDA Fast Track designation for Nectin‑4–positive TNBC.
|
|
| | Regulatory Watch: This Week’s Key Approvals and Milestones
|
|
|
|
|
FDA & Global Watch: Key Approvals This Week
|
|
From oncology and infectious diseases to rare and genetic disorders, this week’s regulatory activity highlights continued momentum in advancing innovative therapies and expanding treatment access across global markets. Here’s a snapshot of the latest approvals, priority reviews, and key regulatory milestones shaping the healthcare landscape:
|
| • | Astellas Pharma and Pfizer received U.S. Food and Drug Administration Priority Review for the combination of Padcev and Keytruda for muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility.
|
|
| • | Sanofi reported FDA approval of Tzield to delay the onset of stage 3 Type 1 Diabetes in pediatric patients aged ≥1 year.
|
|
| • | Merck announced FDA approval of Idvynso for virologically suppressed HIV-1 Infection, further strengthening its infectious disease portfolio.
|
|
| • | Ipsen’s Ojemda (tovorafenib) received conditional approval in the EU for relapsed/refractory BRAF-altered pediatric low-grade glioma (pLGG).
|
|
| • | Regeneron Pharmaceuticals and Sanofi reported FDA approval of Dupixent (dupilumab) for chronic spontaneous urticaria (CSU), expanding its immunology indications.
|
|
| • | DemeRx received FDA IND application acceptance to advance DMX-1001 for Alcohol Use Disorder.
|
|
| • | Regeneron Pharmaceuticals reported FDA accelerated approval of Otarmeni (lunsotogene parvec-cwha) for genetic hearing loss, marking a step forward in gene therapy.
|
|
| • | Arrowhead Pharmaceuticals received a positive opinion from the Committee for Medicinal Products for Human Use for Redemplo (plozasiran) to treat familial chylomicronemia syndrome (FCS).
|
|
|
| | MedTech Advances in Vascular Access & Diagnostics
|
|
|
|
|
Dialysis Access & Women’s Health MedTech Breakthroughs
|
Hemodialysis Vascular Access
|
|
FLEX Vascular presents 12‑month FLEX FIRST AV Registry results at Charing Cross 2026, showing strong safety and durable performance of the FLEX Vessel Prep System in hemodialysis access patients.
|
Key Details
|
| • | Prospective real-world registry (n=130) reported 0% serious adverse events at 30 days and only one minor complication (0.8%).
|
|
| • | At 12 months, target-lesion primary patency reached 40% in cephalic arch lesions and secondary patency was 100% in AV grafts, eliminating roughly one reintervention per patient per year when FLEX was used with PTA.
|
|
Asset Snapshot
|
FLEX Vessel Prep System uses KEMIC (Kinetic Endovascular Micro‑Incision Creation), a purely mechanical, no‑drug, no‑implant approach designed to improve vessel compliance before angioplasty, supporting a differentiated vessel-prep strategy in AV access.
|
|
Revolutionizing Endometrial Cancer Detection: Utepreva's Game-Changing Sampler Hits the Market
|
|
Imagine detecting endometrial cancer before it takes hold—with a single, seamless pass. Utepreva is making that vision real with the launch of its Utepreva Endometrial Sampler, a single-use device engineered for superior tissue capture and rapid diagnostic insights. Set for availability in October 2026, this breakthrough promises to transform early evaluation in women's health.
|
What sets it apart? A triple-threat mechanism in one efficient swipe:
|
| • | Sponge tip soaks up tissue and fluid like a pro.
|
|
| • | Plunger-driven suction pulls in cells while locking them down—no escape, no loss.
|
|
| • | Versatile samples ready for cytologic, histopathologic, and molecular analysis, delivering the full diagnostic picture.
|
|
Backed by rigorous preclinical and design verification testing from Medical Murray, Utepreva crushed the competition: it captured more simulated endometrial tissue, delivered more uniform disruption, and posted statistically significant wins under controlled conditions. Early detection just got a serious upgrade.
|
|
|
Mega-Deals, AI Bets & Clinical Breakthroughs Reshape Biopharma’s Next Frontier
|
This week’s biopharma landscape is defined by bold capital deployment and transformative innovation. Lilly’s ~$7B Kelonia acquisition accelerates in vivo CAR-T and genetic medicines, while Biogen secures global control of felzartamab. Merck’s $1B AI alliance signals a new era of agentic, enterprise-wide transformation. Strategic M&A—from UCB’s regenerative neuroscience push to Amneal’s biosimilars scale-up—highlights long-term portfolio building. Meanwhile, strong clinical momentum across oncology, rare diseases, and immunology, alongside key regulatory wins, underscores a sector rapidly advancing toward more precise, durable, and accessible therapies worldwide.
|
Stay Ahead with PharmaShots Weekly
|
The biopharma world never slows—breakthrough data drops overnight, billion-dollar deals shift competitive landscapes, and regulatory decisions can reshape entire markets in real time. In a sector moving at this speed, timely intelligence isn’t optional—it’s mission-critical.
|
PharmaShots Weekly cuts through the noise, delivering only what matters: pivotal pipeline updates, regulatory milestones, clinical breakthroughs, strategic partnerships, and emerging competitive dynamics—distilled into a crisp, executive-ready briefing you can absorb in minutes.
|
Every Monday at 8:00 AM EST, get a decision-focused snapshot of the forces shaping global pharma and biotech—curated for leaders who act on insight, not overload.
|
If this edition sparked ideas, make it a habit. Subscribe to PharmaShots Weekly for intelligence that is concise, credible, and crafted for decision-makers across R&D, competitive intelligence, strategy, and business development.
|
Know someone who values signal over noise? Forward this edition.
Spotted an insight worth amplifying? Share it on LinkedIn and tag PharmaShots—we love spotlighting sharp industry perspectives.
|
The industry moves fast.
Your intelligence should move faster.
|
| | Tell your success story to the world!
Reach out to us [email protected] for CXO Talks or Viewpoint interview, because your story matters!
|
|
|
|
|
|
0 comments